reference/19005924

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19005924

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Validation Study
endingPage	e166
issn	2352-3026
issueIdentifier	3
pageRange	e154-e166
publicationName	The Lancet. Haematology
startingPage	e154
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_d29184df8844e34b460482b1b6dbad96 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_06aba5a94448c92faf09747c7e7c67bd http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_0071671e0d5c2067c0c3bc602c6c15de http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_8c993673667990800a7d141b5d9d8164
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_df459a95153d909cf9ead00341e05525 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ffe9bc454713460cb9ee1e3d4a7083c3
bibliographicCitation	Cook G, Royle K, Pawlyn C, Hockaday A, Shah V, Kaiser MF, Brown SR, Gregory WM, Child JA, Davies FE, Morgan GJ, Cairns DA, Jackson GH. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. The Lancet Haematology. 2019 Mar;6(3):e154–66. doi: 10.1016/s2352-3026(18)30220-5.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9c47543436459797c4c781bc1d7a4eb0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c4c46ee798cdf93294a426799f68c334 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ffe6fea49bc5022d68f8b8a063436b3a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0fa08a67fb27b509d06683567d900b9e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a98963d3ae0d3fd0b408a25e194a1a2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c623ec3fced76f3b2152f55072ed191f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4ec4b1c11831e0439091b42f855f4503 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4b1150f176280395aa361a9ff1651afd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8f437ee20a744e5a89ebe46f7b5d10e7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e49319fcd0fb881c072c8f0f26eb4e44 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_26b89340e379ee93745e412a4d7b744d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_08f2babb717848db628bd9d724f97a90 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a4fc92e78f283e56dba25c133321bf9e
date	201903
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC6391517 https://pubmed.ncbi.nlm.nih.gov/30738834 https://doi.org/10.1016/s2352-3026%2818%2930220-5
isPartOf	https://portal.issn.org/resource/ISSN/2352-3026 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/43133
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D015233 http://id.nlm.nih.gov/mesh/D009101Q000628
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D004608 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D014180 http://id.nlm.nih.gov/mesh/D011788 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D053208 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D000369
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8530 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6863 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5426 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_a7939d043567ee90a9f1febb314e563d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8561

Showing number of triples: 1 to 56 of 56.